О. I. Ivakhnenko, V. V. Ryazhenov, & N. A. Falaleeva. (2024). Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients. IRBIS LLC.
Chicago Style (17th ed.) CitationО. I. Ivakhnenko, V. V. Ryazhenov, and N. A. Falaleeva. Clinical and Economic Implications of Using Daratumubab with Lenalidomide in the 1st and 2nd Lines of Therapy for Multiple Myeloma Patients. IRBIS LLC, 2024.
MLA (9th ed.) CitationО. I. Ivakhnenko, et al. Clinical and Economic Implications of Using Daratumubab with Lenalidomide in the 1st and 2nd Lines of Therapy for Multiple Myeloma Patients. IRBIS LLC, 2024.
Warning: These citations may not always be 100% accurate.